ABSTRACT Bing‐Neel syndrome (BNS) is a rare complication of Waldenström macroglobulinemia, a condition with low incidence in clinical practice and prone to misdiagnosis. Vigilance is crucial for identifying this condition in patients with Waldenström macroglobulinemia presenting with neurological symptoms. In cases where a pathological biopsy is inconclusive, cerebrospinal fluid flow cytometry can be utilized to aid in diagnosis. Currently, there is no established standard treatment protocol for BNS, and treatment outcomes vary. In this study, a combination of zanubrutinib and R‐CHOP regimen was administered, with zanubrutinib being continued for the management of BNS, resulting in a notably favorable response.
Zhang et al. (Mon,) studied this question.